Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21996313 | 1.00 | BACE1 (0.39) | BACE1BACE2NAAALIPGHDAC4 | |
| SCHEMBL24622085 | 0.94 | BACE1 (0.36) | BACE1BACE2NAAALIPGHDAC4 | |
| SCHEMBL21996508 | 0.89 | ABCB1 (0.41) | BACE1BACE2DDB1CRBN | |
| SCHEMBL24622152 | 0.89 | ABCB1 (0.41) | BACE1BACE2DDB1CRBN | |
| SCHEMBL22047122 | 0.87 | HDAC4 (0.40) | BACE1BACE2NAAALIPGHDAC4 | |
| SCHEMBL21996384 | 0.86 | BACE1 (0.39) | BACE1BACE2NAAALIPGHDAC4 | |
| SCHEMBL21996491 | 0.86 | DRD4 (0.35) | BACE1BACE2DDB1CRBN | |
| SCHEMBL22047547 | 0.86 | DRD4 (0.35) | BACE1BACE2DDB1CRBN | |
| SCHEMBL21996651 | 0.84 | BACE1 (0.38) | BACE1BACE2NAAALIPGHDAC4 | |
| SCHEMBL16434872 | 0.80 | BACE1 (0.49) | BACE1BACE2NAAALIPGDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218661-A1 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218661-A1 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | CBR3, C1R, CBR1 | BACE1 3266/4885BACE2 3077/4885NAAA 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.